dalteparin has been researched along with Osteoporosis in 9 studies
Dalteparin: A low-molecular-weight fragment of heparin, prepared by nitrous acid depolymerization of porcine mucosal heparin. The mean molecular weight is 4000-6000 daltons. It is used therapeutically as an antithrombotic agent. (From Merck Index, 11th ed)
Osteoporosis: Reduction of bone mass without alteration in the composition of bone, leading to fractures. Primary osteoporosis can be of two major types: postmenopausal osteoporosis (OSTEOPOROSIS, POSTMENOPAUSAL) and age-related or senile osteoporosis.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We sought to determine whether long-term prophylactic dalteparin in pregnancy leads to loss of BMD." | 9.12 | Long-term dalteparin in pregnancy not associated with a decrease in bone mineral density: substudy of a randomized controlled trial. ( Clement, AM; Cranney, A; Hague, WM; Hodsman, A; Kahn, SR; Kovacs, MJ; Lazo-Langner, A; Rodger, MA, 2007) |
| "Objective This study was performed to evaluate the efficacy of rivaroxaban versus nadroparin for preventing deep venous thrombosis (DVT) in elderly patients with osteoporosis undergoing initial total hip arthroplasty (THA) for femoral neck fractures." | 7.88 | Rivaroxaban versus nadroparin for preventing deep venous thrombosis after total hip arthroplasty following femoral neck fractures: A retrospective comparative study. ( Chen, D; Ge, Z; Liang, G; Wan, Z; Xu, B; Yang, C; Yu, W; Zeng, X; Zhang, C; Zhang, F; Zhang, X, 2018) |
| "We sought to determine whether long-term prophylactic dalteparin in pregnancy leads to loss of BMD." | 5.12 | Long-term dalteparin in pregnancy not associated with a decrease in bone mineral density: substudy of a randomized controlled trial. ( Clement, AM; Cranney, A; Hague, WM; Hodsman, A; Kahn, SR; Kovacs, MJ; Lazo-Langner, A; Rodger, MA, 2007) |
| " In a randomised open study, 44 pregnant women with confirmed previous or current thromboembolism were randomised to receive either low-molecular-weight heparin, dalteparin (N = 21) once daily subcutaneously or unfractionated sodium heparin (UF heparin, N = 23) twice daily subcutaneously for thromboprophylaxis during pregnancy and puerperium." | 5.10 | Postpartum bone mineral density in women treated for thromboprophylaxis with unfractionated heparin or LMW heparin. ( Hiilesmaa, V; Kaaja, R; Leinonen, P; Markkola, A; Pettilä, V, 2002) |
| "Objective This study was performed to evaluate the efficacy of rivaroxaban versus nadroparin for preventing deep venous thrombosis (DVT) in elderly patients with osteoporosis undergoing initial total hip arthroplasty (THA) for femoral neck fractures." | 3.88 | Rivaroxaban versus nadroparin for preventing deep venous thrombosis after total hip arthroplasty following femoral neck fractures: A retrospective comparative study. ( Chen, D; Ge, Z; Liang, G; Wan, Z; Xu, B; Yang, C; Yu, W; Zeng, X; Zhang, C; Zhang, F; Zhang, X, 2018) |
| "Fondaparinux did not inhibit osteoblast proliferation in vitro and may reduce the risk of heparin-induced osteoporosis associated with long-term heparin administration." | 3.73 | Effect of low molecular weight heparin (dalteparin) and fondaparinux (Arixtra) on human osteoblasts in vitro. ( Handschin, AE; Hoerstrup, SP; Kock, HJ; Trentz, O; Trentz, OA; Wanner, GA, 2005) |
| "Osteoporosis is a rare but potentially severe complication under high-dose, long-term unfractionated heparin therapy." | 1.31 | Osteoblast growth inhibition by unfractionated heparin and by low molecular weight heparins: an in-vitro investigation. ( Handschin, AE; Kock, HJ, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (22.22) | 18.2507 |
| 2000's | 5 (55.56) | 29.6817 |
| 2010's | 2 (22.22) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Zhang, C | 1 |
| Xu, B | 1 |
| Liang, G | 1 |
| Zeng, X | 1 |
| Yang, C | 1 |
| Zhang, F | 1 |
| Wan, Z | 1 |
| Yu, W | 1 |
| Chen, D | 1 |
| Ge, Z | 1 |
| Zhang, X | 1 |
| Kock, HJ | 2 |
| Handschin, AE | 2 |
| Martineau, P | 1 |
| Tawil, N | 1 |
| San Juan Alvarez, M | 1 |
| Márquez Garrido, G | 1 |
| Rodríguez Bertos, C | 1 |
| González Pérez, L | 1 |
| Gates, S | 1 |
| Brocklehurst, P | 1 |
| Ayers, S | 1 |
| Bowler, U | 1 |
| Trentz, OA | 1 |
| Hoerstrup, SP | 1 |
| Wanner, GA | 1 |
| Trentz, O | 1 |
| Rodger, MA | 1 |
| Kahn, SR | 1 |
| Cranney, A | 1 |
| Hodsman, A | 1 |
| Kovacs, MJ | 1 |
| Clement, AM | 1 |
| Lazo-Langner, A | 1 |
| Hague, WM | 1 |
| Shefras, J | 1 |
| Farquharson, RG | 1 |
| Pettilä, V | 1 |
| Leinonen, P | 1 |
| Markkola, A | 1 |
| Hiilesmaa, V | 1 |
| Kaaja, R | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effects of UFH and LMWH on Osteoprotegerin and RANKL Plasma Levels in Hemodialysis Patients[NCT00669721] | 40 participants (Anticipated) | Interventional | 2008-03-31 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for dalteparin and Osteoporosis
| Article | Year |
|---|---|
Low-molecular-weight heparins in the treatment of deep-vein thrombosis.
Topics: Blood Platelets; Capillary Permeability; Dalteparin; Enoxaparin; Fibrinolytic Agents; Hemorrhage; He | 1998 |
3 trials available for dalteparin and Osteoporosis
| Article | Year |
|---|---|
Thromboprophylaxis and pregnancy: two randomized controlled pilot trials that used low-molecular-weight heparin.
Topics: Adult; Cesarean Section; Enoxaparin; Female; Fibrinolytic Agents; Humans; Osteoporosis; Patient Sele | 2004 |
Long-term dalteparin in pregnancy not associated with a decrease in bone mineral density: substudy of a randomized controlled trial.
Topics: Adult; Anticoagulants; Bone Density; Bone Diseases, Metabolic; Dalteparin; Female; Humans; Middle Ag | 2007 |
Postpartum bone mineral density in women treated for thromboprophylaxis with unfractionated heparin or LMW heparin.
Topics: Absorptiometry, Photon; Adult; Anticoagulants; Bone Density; Dalteparin; Factor Xa Inhibitors; Femal | 2002 |
5 other studies available for dalteparin and Osteoporosis
| Article | Year |
|---|---|
Rivaroxaban versus nadroparin for preventing deep venous thrombosis after total hip arthroplasty following femoral neck fractures: A retrospective comparative study.
Topics: Aged; Arthroplasty, Replacement, Hip; Blood Coagulation; Demography; Female; Femoral Neck Fractures; | 2018 |
Osteoblast growth inhibition by unfractionated heparin and by low molecular weight heparins: an in-vitro investigation.
Topics: Adult; Anticoagulants; Cell Culture Techniques; Cell Division; Dalteparin; Enoxaparin; Heparin; Hepa | 2002 |
[Hip fracture during pregancy in a woman with transient osteporosis].
Topics: Accidental Falls; Adult; Anticoagulants; Bone Screws; Cesarean Section; Female; Fracture Fixation, I | 2010 |
Effect of low molecular weight heparin (dalteparin) and fondaparinux (Arixtra) on human osteoblasts in vitro.
Topics: Alkaline Phosphatase; Anticoagulants; Cells, Cultured; Dalteparin; Fluoresceins; Fondaparinux; Gene | 2005 |
Bone density studies in pregnant women receiving heparin.
Topics: Anticoagulants; Antiphospholipid Syndrome; Bone Density; Case-Control Studies; Dalteparin; Female; H | 1996 |